Production (Stage)
Hemostemix Inc.
HEM.V
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 238.78% | -24.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 238.78% | -24.02% | |||
| Operating Income | -238.78% | 24.02% | |||
| Income Before Tax | -304.90% | 39.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -304.90% | 39.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -304.90% | 39.24% | |||
| EBIT | -238.78% | 24.02% | |||
| EBITDA | -238.78% | 24.02% | |||
| EPS Basic | -203.85% | 40.91% | |||
| Normalized Basic EPS | -176.47% | 37.04% | |||
| EPS Diluted | -203.85% | 40.91% | |||
| Normalized Diluted EPS | -176.47% | 37.04% | |||
| Average Basic Shares Outstanding | 36.44% | 0.00% | |||
| Average Diluted Shares Outstanding | 36.44% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||